Literature DB >> 32813941

A SARS-CoV-2 mRNA Vaccine - Preliminary Report.

Juergen R Schaefer1, Yulia Sharkova1, Tanja Nickolaus1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32813941     DOI： 10.1056/NEJMc2026616

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

Review 1.  COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants.

Authors:  Suganya Panneer Selvam; Pratibha Ramani; Ramya R; Sandhya Sundar; Lakshmi T A
Journal:  Cureus       Date:  2022-05-11

Review 2.  COVID-19-from mucosal immunology to IBD patients.

Authors:  Carl Weidinger; Ahmed Nabil Hegazy; Rainer Glauben; Britta Siegmund
Journal:  Mucosal Immunol       Date:  2021-02-19       Impact factor: 7.313

3.  Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19.

Authors:  Bin Zheng; Wenchang Peng; Mingming Guo; Mengqian Huang; Yuxuan Gu; Tao Wang; Guangjian Ni; Dong Ming
Journal:  Chem Eng J       Date:  2021-03-19       Impact factor: 13.273
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.